| Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2018: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2017: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2016: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Outline of Final Research Achievements |
Thirty-three post-surgical patients receiving continuous intravenous dexmedetomidine were enrolled. Blood specimens and clinical data (included RCSQ) were sampling 12-h after starting administration of dexmedetomidine. The medians (interquartile range) of the concentration, area under the concentration;time curve of dexmedetomidine from 0 to 12 h (AUC0-12), apparent elimination half-life, distribution volume, and total clearance were 0.54 ng/mL (0.37, 0.64 ng/mL), 4.27 ng h/mL (2.92, 5.60 ng h/mL), 5.72 h (5.23, 6.22 h), 228 L (160, 313 L) and 29.4 mL/h (21.2, 37.0 mL/h), respectively. Distribution volume and total clearance of dexmedetomidine were correlated with the elevation ratio of creatinine clearance. The medians (interquartile range) of RCSQ were 66.2（32.4, 87.8）mean mm, and AUC and plasma concentration of dexmedetomidine were higher in patients with above 76 mean mm for RCSQ.
|
